| Company Name: |
Tianjin Anhao Biological Technology Co., Ltd.
|
| Tel: |
|
| Email: |
sales@ahpharmatech.com |
| Products Intro: |
Product Name:4-(3-(1-benzhydryl-5-chloro-2-(2-((3,4-dichlorophenyl)methylsulfonamido)ethyl)-1H-indol-3-yl)propyl)benzoic acid
CAS:381683-94-9
Purity:97% Package:1g; 5g; 25g; 1kg; 25kg Remarks:L-2455
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:Efipladib
CAS:381683-94-9
Package:50mg/RMB 18300;100mg/RMB 23500;25mg/RMB 13900
|
EFIPLADIB manufacturers
- Efipladib
-
- $2580.00 / 50mg
-
2025-10-27
- CAS:381683-94-9
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | EFIPLADIB Basic information |
| Product Name: | EFIPLADIB | | Synonyms: | EFIPLADIB;4-(3-(5-chloro-2-(2-(((3,4-dichlorobenzyl)sulfonyl)aMino)ethyl)-1-(diphenylMethyl)-1H-indol-3-yl)propyl)benzoic acid;4-(3-(1-benzhydryl-5-chloro-2-(2-((3,4-dichlorophenyl)MethylsulfonaMido)ethyl)-1H-indol-3-yl)propyl)benzoic acid;PLA-902;PLA902;PLA 902;Benzoic acid, 4-[3-[5-chloro-2-[2-[[[(3,4-dichlorophenyl)methyl]sulfonyl]amino]ethyl]-1-(diphenylmethyl)-1H-indol-3-yl]propyl]-;Efipladib
(PLA 902) | | CAS: | 381683-94-9 | | MF: | C40H35Cl3N2O4S | | MW: | 746.14 | | EINECS: | | | Product Categories: | | | Mol File: | 381683-94-9.mol |  |
| | EFIPLADIB Chemical Properties |
| Boiling point | 891.2±75.0 °C(Predicted) | | density | 1.32±0.1 g/cm3(Predicted) | | pka | 4.34±0.10(Predicted) |
| | EFIPLADIB Usage And Synthesis |
| Uses | Treatment of pain and symptomatic management of arthritis. | | in vivo | Efipladib (100 mg/kg; p.o.; BID for 31 days) reverses the severity in mouse collagen-induced arthritis (CIA) model[1].
Efipladib (100 mg/kg; p.o.; once) significantly inhibits the nociceptive response 1 h after administration in the rat Complete Freund’s Adjuvant (CFA) nociception model[2].
Efipladib is unable to cross the BBB to gain access to the central compartment[2].
Efipladib (100 nM; IT; 5 μL) reduces PGE2 levels in the cerebrospinal fluid in rats[2]. | Animal Model: | Mouse collagen-induced arthritis (CIA) model[1] | | Dosage: | 100 mg/kg | | Administration: | PO, BID for 31 days | | Result: | Gave a dramatic reduction in the clinical disease severity score relative to the vehicle treated group. |
| Animal Model: | Male Sprague-Dawley rats[2] | | Dosage: | 100 nM in 5 μL of 100% DMSO/rat | | Administration: | Intrathecal administration | | Result: | Reduced PGE2 levels in the cerebrospinal fluid (CSF) by 45-60%, yet there was no effect on the nociceptive response. |
| | IC 50 | cPLA2α: 0.04 μM (IC50); cPLA2α: 0.067 μM (Ki) |
| | EFIPLADIB Preparation Products And Raw materials |
|